OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
266
Results
Show all
Save search
Copy query
Show results for
Unknown
(264)
Proteomics
(2)
Organisms
Bordetella genomosp. 7
(2)
Jiangella gansuensis
(2)
Nocardiopsis valliformis
(2)
Cheiracanthium punctorium
(2)
Promicromonospora sukumoe
(2)
Fusarium avenaceum
(2)
Cyphellophora europaea
(2)
Crenobia alpina
(2)
Caretta caretta
(2)
Pseudonocardia ammonioxydans
(2)
bacterium
(2)
Theileria annulata strain Ankara
(2)
Mycobacterium xenopi RIVM700367
(2)
Epinephelus coioides
(2)
Sulfolobus acidocaldarius DSM 639
(2)
Acinetobacter baumannii 44298_5
(2)
Pleurotus ostreatus PC9
(2)
Mesomycoplasma hyopneumoniae J
(2)
Mesomycoplasma hyopneumoniae 7448
(2)
Acetivibrio thermocellus DSM 1313
(2)
Litomosoides sigmodontis
(2)
Flaveria ramosissima
(2)
NEWT:2172651
(2)
Phycis phycis
(2)
Plasmodium falciparum Mad71/Papua New Guinea
(2)
Pinctada fucata
(2)
Fonsecaea pedrosoi CBS 271.37
(2)
Campylobacter jejuni 10186
(2)
Bubalus bubalis bubalis
(2)
Saccharomyces uvarum
(2)
Repository
pride
(2)
Tissue
T cell
(2)
Blood
(1)
Disease
Neurodevelopmental delay
(1)
Technology Type
Mass Spectrometry
(2)
Affinity proteomics
(1)
DiaPASEF
(1)
All-ion fragmentation
(1)
Bottom-up proteomics
(1)
Data-independent acquisition
(1)
Publication Date
2025
(2)
Release Date
2021
(41)
2022
(37)
2025
(31)
2020
(29)
2024
(23)
2023
(22)
2014
(14)
2019
(13)
2015
(9)
2012
(9)
2016
(7)
2026
(5)
2017
(5)
2013
(4)
2011
(4)
2018
(3)
2009
(2)
2008
(2)
2007
(2)
2010
(1)
2006
(1)
Lab affiliation
95 Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UT3), Toulouse, 31077, France
(1)
Universitätsmedizin Greifswald Interfakultäres Institut für Genetik und Funktionelle Genomforschung Abteilung für Funktionelle Genomforschung Felix-Hausdorff-Straße 8 17487 Greifswald
(1)
Previous
page
1 / 27
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
27
Next
page
Sort
by:
Relevance
Page size
10
Multitarget nociceptor sensitization by a promiscuous peptide from the venom of the King Baboon spider.
Not available
S-EPMC8812547
|
biostudies-literature
Cite
Repurposing benzimidazole and benzothiazole derivatives as potential inhibitors of SARS-CoV-2: DFT, QSAR, molecular docking, molecular dynamics simulation, and
in-silico
pharmacokinetic and toxicity studies.
Not available
S-EPMC8496942
|
biostudies-literature
Cite
A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells.
Not available
S-EPMC9024838
|
biostudies-literature
Cite
Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment.
Not available
S-EPMC4070518
|
biostudies-literature
Cite
Proproliferative function of adaptor protein GRB10 in prostate carcinoma.
Not available
S-EPMC6404554
|
biostudies-literature
Cite
Rational engineering of minimally immunogenic nucleases for gene therapy.
Not available
S-EPMC11696374
|
biostudies-literature
Cite
Immunoinformatics-Aided Design of a Peptide Based Multiepitope Vaccine Targeting Glycoproteins and Membrane Proteins against Monkeypox Virus.
Not available
S-EPMC9693848
|
biostudies-literature
Cite
High serum level of matrix metalloproteinase 9 and promoter polymorphism - 1562 C:T as a new risk factor for metabolic syndrome.
Not available
S-EPMC4216523
|
biostudies-literature
Cite
Molecular Docking studies of D2 Dopamine receptor with Risperidone derivatives.
Not available
S-EPMC3916812
|
biostudies-literature
Cite
Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14<sup>®</sup>) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study.
Not available
S-EPMC12010144
|
biostudies-literature
Cite
Previous
page
1 / 27
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
27
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets